Table 2.
Outcomes after RIC/NMA HCT based on cytarabine consolidation exposure: univariate analysis
| No Cytarabine consolidation | Cytarabine consolidation | P-value | |||
|---|---|---|---|---|---|
| N eval. | Incidence (95% CI) | N eval. | Incidence (95% CI) | ||
| OS | |||||
| @ 2 year | 202 | 42 (35–49) | 402 | 47 (42–52) | 0.25 |
| @ 3 year | 202 | 36 (29–43) | 402 | 42 (37–47) | 0.16 |
| Relapse | |||||
| @ 2 year | 197 | 33 (27–40) | 393 | 37 (32–41) | 0.42 |
| @ 3 year | 197 | 37 (30–44) | 393 | 38 (33–43) | 0.80 |
| aGVHD III–IV | 202 | 402 | |||
| @ Day +100 | 16(12–22) | 13(10–16) | 0.26 | ||
| cGVHD | 195 | 395 | |||
| @ 3 year | 41(34–49) | 41(36–47) | 0.96 | ||
| TRM | |||||
| @ 100 days | 197 | 12 (8–17) | 393 | 5 (4–8) | 0.01 |
| @ 1 year | 197 | 23 (17–29) | 393 | 16 (12–20) | 0.04 |
| DFS | |||||
| @ 2 year | 197 | 39 (32–46) | 393 | 44 (39–49) | 0.20 |
| @ 3 year | 197 | 34 (27–41) | 393 | 41(35–46) | 0.15 |